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Abstract
End-stage renal disease (ESRD) patients present high incidence of cardiovascular (CV) 
events, which are the most common causes of death in these patients. The occurrence 
of CV events appears as a consequence of the high prevalence of traditional and non-
traditional CV risk factors. Online-hemodiafiltration (OL-HDF) was introduced as a 
better alternative to conventional dialysis, as it was proposed to be more biocompat-
ible, to increase dialysis efficacy, to reduce the inflammatory response to treatment and 
to improve patient’s quality of life, contributing to reduce CV and all-cause mortality 
risk in ESRD. However, data in literature, comparing the effect of OL-HDF with con-
ventional dialysis for clinical CV outcome and all-cause mortality, yielded controversy 
about those benefits of OL-HFD over standard hemodialysis. A review of the tradi-
tional CV risk factors (e.g., arterial hypertension, diabetes mellitus, dyslipidemia, obe-
sity, smoking and advanced age), non-traditional risk factors (e.g., anemia, oxidative 
stress, hyperphosphatemia, endothelial dysfunction, left ventricular hypertrophy, insu-
lin resistance, high levels of lipoprotein(a) and inflammation) and potential renocardio-
vascular biomarkers, in the setting of ESRD, is presented. The impact of conventional 
hemodialysis and OL-HDF on CV risk factors and on the outcome of ESRD patients is 
also addressed.
Keywords: cardiovascular risk factors, hemodialysis, online-hemodiafiltration,  
end-stage renal disease, inflammation, anemia
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Chronic kidney disease (CKD) prevalence is increasing worldwide and became an actual 
health challenge. CKD is a term used to refer heterogeneous disorders affecting kidney struc-
ture and function with variable clinical presentation which result in gradual to permanent 
loss of kidney function over time. Patients at higher risk for CKD include those with meta-
bolic disorders, such as diabetes mellitus, obesity and amyloidosis, with arterial hyperten-
sion, renal vascular disorders, immunologic disorders, infections, primary tubular disorders 
(nephrotoxins), urinary tract obstruction (hypertrophy of prostate or renal calculi) and con-
genital disorders [1].
The two most common causes of CKD are diabetes and arterial hypertension; glomerulone-
phritis, nephrolithiasis and polycystic kidney disease are other, less common causes [2].
The patients at early stages of CKD (stages 1 and 2) are, usually, asymptomatic, showing kid-
ney damage and/or loss of kidney function, with a significant risk for disease progression. At 
stages 3 and 4, worsening of the disease is associated with kidney dysfunction that progresses 
from mildly to severely decreased; in end-stage renal disease (ESRD), stage 5, an irreversible 
loss of renal function occurs. These patients require renal replacement therapy, such as dialy-
sis or kidney transplantation.
Figure 1. Traditional, non-traditional and potential renocardiovascular biomarkers in end-stage renal disease (ESRD). 
The high incidence of cardiovascular (CV) risk factors in ESRD contributes to the close relationship between CV disease 
(CVD) and ESRD (ADMA, asymmetric dimethylarginine; BNP, B-type natriuretic peptide; CRP, C-reactive protein; 
FGF-23, fibroblast growth factor-23; GDF-15, growth differentiation factor-15; KIM-1, kidney injury molecule-1; Lp(a), 
lipoprotein(a); MMP, matrix-metalloproteases; NGAL, neutrophil gelatinase-associated lipocalin; NT-proBNP, BNP 
amino-terminal fragment; PTX3, pentraxin 3).
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ESRD is a growing public health problem, given the increasing prevalence worldwide and its 
socioeconomic consequences. By 2020, it is estimated that the number of ESRD patients rises 
by 60%, as compared to the number of patients recorded in 2005 [3]. Mortality rate is 10- to 
20-fold higher in ESRD patients than in general population [4]. These patients commonly 
present chronic inflammation, malnutrition and progressive cardiovascular disease (CVD) 
that is the most common cause of mortality (about 50%) [5]. These features have a consider-
able impact on functional status and health-related quality of life (HRQoL) of ESRD patients.
Dialysis therapies by using semipermeable membranes mimic renal function, removing the 
excess of water and waste products. Efficient cleansing of the blood from relevant uremic 
toxins, fluid and salt overload, is the prior goal of all dialysis therapies. Currently, differ-
ent dialysis modalities, including peritoneal dialysis, hemodialysis and hemodiafiltration, are 
used for chronic and acute treatment of renal failure.
ESRD leads to impairment of HRQoL of the patients and to a higher risk of morbidity and 
mortality. Patients with ESRD present a higher incidence of CV events, as a result of the 
increased prevalence of CV risk factors, either traditional or non-traditional (Figure 1).
2. Cardiovascular risk factors
In the last two decades, the better understanding of uremic toxicity, salt and water control 
contributed to improve the CKD-associated comorbidities. Moreover, the recent advances in 
dialysis techniques have provided more efficient, controlled and safer dialysis procedures. In 
spite of these improvements, hemodialysis (HD) patients still present poor outcomes, with 
low survival rates, as compared to general population [6]. Morbidity and mortality in HD 
patients remains high in Europe and is higher in the United States [7]. CVD is the most com-
mon cause of death in CKD patients.
Based on the World Health Organization mortality database, Yoshino et al. [8] reported a close 
correlation between all-cause mortality rates and atherosclerotic CV disease mortality in the 
general population and that this correlation was even stronger for dialysis patients. United 
States Renal Data System (USRDS) 2013 Annual Data Report indicated that CKD patients 
have higher rates of congestive heart failure (CHF), acute myocardial infarction (AMI), cere-
brovascular accidents and lower survival rates, as compared to non-CKD patients. Survival 
appears to decrease with severity of CKD [9]. Heart failure has been strongly related to CKD 
[10], suggesting a significant impact of the disease on cardiac structure and function.
The high incidence of CVD in CKD patients may result from the high prevalence of traditional 
CV risk factors and from other CKD-specific risk factors. In ESRD patients, worsening of the 
disease and the hemodialysis procedure may underlie the increased CV risk observed in these 
patients.
2.1. Traditional cardiovascular risk factors
Traditional CVD risk factors include diabetes mellitus, arterial hypertension, dyslipidemia, 
obesity, sedentarism, smoking habits, as well as advanced age.
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2.1.1. Diabetes and hypertension
The MADIABETES Cohort Study showed that the coexistence of CKD in patients with type 2 
diabetes mellitus was an independent risk factor for all-cause and CV mortality [11].
Arterial hypertension and diabetes, the main causes of CKD, lead to low glomerular fil-
tration rate (GFR) and high albuminuria, inducing left ventricular hypertrophy and, 
subsequently, diastolic dysfunction of left ventricle [12]. It is known that albuminuria/
proteinuria excretion is a marker of kidney damage and a risk factor for progression of 
kidney disease. More recently, it has been proposed to have a direct impact on CVD events 
in CKD patients. A prospective, population-based cohort study including 16,958 patients 
conducted in Iceland, showed that CKD patients at stage 3b or stage 4 had the highest risk 
for coronary heart disease (CHD); however, there was also a significant 1.55-fold increase 
in the risk of CHD in those patients with a GFR of at least 90 mL/min/1.73 m2 with pro-
teinuria (stage 1 CKD), and a significant 1.72-fold increase in risk of CHD in those with a 
GFR of 60–89 mL/min/1.73 m2 with proteinuria (stage 2 CKD), as compared to the refer-
ence group without proteinuria [13]. According to Matsushita et al. [14], albuminuria is 
independently associated with heart mass, systolic and diastolic functions of left ventricle. 
The level of albumin is currently considered as a potential predictor of mortality and hos-
pitalization risk [15].
Hypertension is found in 80–85% of CKD patients, and its etiology is multifactorial. The CKD 
per se favors the development of hypertension by activating renin-angiotensin and sympa-
thetic nerve systems [16]. The activity of the sympathetic nervous system is enhanced in CKD 
patients, as a result of overspill and reduced catecholamine clearance, increasing vascular 
resistance and systemic blood pressure [17].
2.1.2. Dyslipidemia
CKD has been associated with an abnormal lipid profile, due to alterations in lipid metabo-
lism; the most common changes in lipid profile include an increase in triglycerides (TG), lipo-
protein (Lp)(a) and oxidized lipids, and a reduction in high-density lipoprotein cholesterol 
(HDLc) values. The hypertriglyceridemia may be explained by the increase in apolipoprotein 
C-III and by the reduction of lipoprotein lipase activity, reducing their clearance [18]. The 
decreased production of apolipoprotein A-1 with worsening of renal failure and the reduced 
activity of lecithin-cholesterol acyltransferase contribute to the reduction in HDL production 
[19]. Raised values of TG/HDLc ratio seem to be a predictor of poor CVD outcome in CKD 
patients [20].
In ESRD patients, the oxidative stress and the reduction in paraoxonase and glutathione per-
oxidase activities may compromise the antioxidant and anti-inflammatory properties of HDL 
that becomes dysfunctional [19]. These changes also explain the increase in oxidized low-
density lipoproteins (oxLDL) and in oxLDL/LDLc ratio in CKD patients on dialysis [21]. The 
oxidative modifications in LDL are important for the initiation and progression of atheroscle-
rosis and are well-known CVD risk factors.
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2.1.3. Obesity
Obesity is a well-known CV risk factor that favors several comorbidities, such as type 2 dia-
betes, hypertension, dyslipidemia, cancer and sleep apnea. A meta-analysis that included 25 
cohorts, 3 cross-sectional and 19 case-control studies reported that obesity also increases the 
risk for kidney disease in the general population [22]. There are several mechanisms through 
which obesity predisposes to CKD. High body fat mass favors mesangial expansion, increases 
renal metabolic demand, promoting glomerular hyperfiltration and hypertrophy, reduced 
podocyte density and increased filtration fraction, contributing to kidney damage and pro-
gression to ESRD [23]. The pattern of risk associated with obesity is different for ESRD on 
dialysis therapy, as these patients present a lower CV morbidity and mortality, known as 
“obesity paradox;” actually, morbidly obese HD patients present the lowest mortality rate 
[24]. Apparently, increased muscle and body fat mass promote longevity in advanced CKD.
Considering the continuous worldwide increase in obesity, it must be considered as an emerg-
ing problem for nephrologists and endocrinologists, deserving a especial care.
2.1.4. Smoking
Smoking habits, as obesity, is a major modifiable CV risk factor. Smokers, CKD patients 
without established CVD, have been associated with 59% increase in heart failure and 68% 
increase in peripheral vascular disease, as compared to non-smokers, in a follow-up study of 
2.2 years [25].
The intervention of clinicians, in case of obesity and/or smoking habits, would contribute to 
minimize renal damage and progression of the disease; moreover, given the prevalence of 
CVD events, it would reduce morbidity and mortality in CKD patients.
2.2. Non-traditional cardiovascular risk factors
The non-traditional CV risk factors in CKD patients include the associated complications of 
the disease that usually grow worse in patients on dialysis therapy.
2.2.1. Anemia and inflammation
Anemia and inflammation are common features in CKD that increase as kidney function 
declines. Anemia is mainly due to the reduced production of erythropoietin (EPO) by the fail-
ing kidneys, leading to hypoxia that favors a local renal inflammatory process. In patients on 
HD, inflammation is enhanced, particularly in those using central venous catheter (CVC) for 
the vascular access in HD procedure. This type of vascular access is more prone to infection 
or inflammation, and thus, it might be associated with poor outcome of HD patients. Markers 
of inflammation, such as C-reactive protein (CRP) [26] and inflammatory cytokines [27], are 
raised in CKD patients, particularly in HD patients. In a recent study by our team, we found 
that CRP, malnutrition and the use of CVC were independent risk factors for mortality in HD 
patients [28].
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Some uremic toxins express potent pro-inflammatory and oxidative activity [29], contribut-
ing to amplify inflammation and oxidative injuries to cells and plasma constituents. Dialysis 
therapy may directly benefit bone marrow erythropoiesis, by removing substances that 
inhibit erythropoiesis. Nowadays, HD membranes are highly biocompatible; however, long-
term intradialytic contact of blood with large surfaced artificial materials leads to continuous 
inflammatory cell activation, with release of cytokines and reactive oxygen species (ROS) and 
nitric oxide production.
Apparently, inflammation and oxidative stress play crucial roles in the progression of CKD 
and in the risk for CVD events [30]. Inflammation is also associated with endothelial dys-
function, which is observed even in the initial phases of CKD [31]. Moreover, inflammation 
seems to be independently associated with anemia and malnutrition, leading to accelerated 
atherosclerosis, CV complications or even death [32]. Actually, it was recently recommended 
to monitor inflammation through the evaluation of inflammatory markers in CKD patients, 
since persistent inflammation may be a silent reflection of pathophysiologic disturbances [33]. 
CRP seems to be the most useful biomarker in clinical practice for guidance of inflammation 
and to estimate risk in CKD patients [33].
Anemia can lead to adverse clinical effects, namely reduction in tissue oxygenation, increase 
in cardiac output, left ventricular hypertrophy, congestive heart disease, fatigue, reduction in 
exercise capacity, and immunodeficiency. Besides the insufficient renal production of EPO, 
other factors may contribute to enhance anemia. Uremic toxins are able to suppress erythro-
poiesis, by inhibiting proliferation of erythroid progenitors [34]. The activation of inflamma-
tory cells is accompanied by the release of inflammatory cytokines, as interleukin (IL)-6 that 
triggers the synthesis of hepcidin, by the liver. This glycoprotein, increased in CKD patients, 
is the main regulator of iron metabolism. Hepcidin reduces iron absorption through entero-
cytes and the mobilization of iron from macrophages of the reticuloendothelial system, lead-
ing to a functional iron deficiency that will further worsen anemia. Increasing hepcidin levels, 
decreasing EPO levels and increasing impairment of kidney function were reported as inde-
pendent predictors of mortality in CKD diabetic patients [35].
Chronic blood loss, due to bleeding events, accidental losses, excessive blood drawn for labo-
ratory tests, and blood lost within dialysis circuit after HD sessions, may also contribute to 
the anemic state [34].
It is also important to refer that erythrocytes of patients with CKD are more prone for prema-
ture removal, showing a shorter life span. Changes in erythrocyte membrane protein com-
position, namely in spectrin and band 3, have been reported in HD patients. Alterations in 
membrane protein interactions may lead to destabilization of membrane structure, favoring a 
premature removal of the erythrocytes [36].
2.2.2. Oxidative stress
An enhanced production of ROS and a decrease in antioxidants favor oxidative stress, a 
common condition in ESRD. This imbalance of oxidants/antioxidants favors tissue dam-
age, through lipid, protein, and DNA oxidation, that may lead to endothelial dysfunction 
and atherosclerosis [37]. As referred previously, increased levels of oxLDL, a key player in 
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the  initiation and progression of atherosclerosis, and a higher oxLDL/LDLc ratio have been 
reported in CKD patients on dialysis [21]. Products of lipid peroxidation, such as malondi-
aldehyde and hydroperoxide, are increased in CKD, being the latter reported as a reliable 
marker of oxidative injury during HD [38]. Advanced oxidation protein products accumulate 
in CKD, especially in HD patients, and have been reported as independent risk factors for 
ischemic heart disease [39]. Moreover, HD seems to contribute to oxidative stress being asso-
ciated with increased synthesis of pro-inflammatory cytokines, phagocyte oxidative burst, 
activation of NADPH oxidase, and antioxidant removal by dialysis [40].
2.2.3. Other factors
Several other uremic-related factors may also play an important role in CVD risk of these 
patients, namely multiple comorbid conditions, fluid overload, hyperphosphatemia, endo-
thelial dysfunction, left ventricular hypertrophy, insulin resistance (IR), hyper-homocystein-
emia and high levels of Lp(a).
Lipoprotein(a), known as an independent risk factor for CVD, is increased in HD patients [21], 
but the mechanism explaining this rise is still poorly understood. It has been suggested that 
it results, mainly, from a decrease in Lp(a) clearance, than from an increased production [41].
The atherothrombogenicity of Lp(a) is associated with a structural homology of apo(a) and 
plasminogen that seems to lead to a competition for the linkage to fibrin, inhibiting fibrino-
lysis. Lp(a) as LDL is crucial for the initiation, progression and rupture of the atherosclerotic 
plaque; the oxidation of apo(a) triggers the binding to scavenger receptors on macrophages 
and the avid uptake of Lp(a).
Mild-to-moderate CKD patients, and even those with a GFR within normal values, often 
develop IR. In ESRD patients, IR has been linked to protein energy wasting and malnutrition 
and appears as an independent predictor for CVD [42].
Hyperphosphatemia is a marker of kidney function decline and has been reported as a marker 
of increased risk for CVD events and mortality [43].
Coronary artery calcification has a significant incidence in patients with CKD. Recently, Chen 
et al. [44] reported that in CKD patients, coronary artery calcification is independently and 
strongly associated with risk for CVD, myocardial infarction, heart failure and all-cause mor-
tality. The authors suggested the inclusion of coronary artery calcification as a criteria for risk 
stratification and prediction of CVD among CKD patients [44].
A recent study by Chen et al. [45] in CKD patients showed that inflammation, prothrombotic 
state, oxidative stress, IR, enhanced glycated hemoglobin and increased alkaline phosphatase 
are associated with an increased risk for peripheral arterial disease, independent of tradi-
tional risk factors.
2.3. Renocardiovascular markers
Cardiorenal syndrome traduces the close relationship between CVD and CKD [46]; in these 
conditions, the dysfunction in one organ often induces a dysfunction in the other.
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Given the high prevalence of CVD in CKD patients, particularly in those on hemodialysis, 
some biomarkers, pertinent for both conditions, have emerged and were defined as renocar-
diovascular biomarkers [47]. Several hormones, biomarkers of cardiac injury, oxidative stress, 
renal damage and inflammation have been proposed for the group of potential biomarkers of 
cardiorenal syndrome [47] (Figure 1).
Natriuretic peptides and related peptides, endothelin, argine vasopressin, copeptin and adre-
nomedullin are some of the neurohormones under study as cardiorenal syndrome biomarkers.
2.3.1. B-type natriuretic peptide
B-type natriuretic peptide (BNP) and its amino-terminal fragment (NT-proBNP), produced when 
hemodynamic load occurs, seem to be the best markers for heart failure and are also used for 
other CVD [47, 48]. Both BNP and NT-proBNP seem to be also valuable biomarkers for progres-
sion of CKD, prediction of mortality and stratification of CV risk in patients in dialysis [49, 50].
2.3.2. Copeptin
Copeptin, the C-terminal part of pro-arginine vasopressin is known as a substitute marker of 
arginine vasopressin; it has been associated with CV and all-cause mortality in type 2 diabetes 
mellitus patients treated in primary care [51]. Fenske et al. [52] reported that copeptin showed 
significant associations with stroke, sudden death, combined CV events and mortality, in 
type 2 diabetes mellitus patients on hemodialysis, but not with myocardial infarction or death 
caused by CHF. However, the value of copeptin and arginine vasopressin as biomarkers of 
CVD in CKD may be limited, as the impairment in renal function seems to introduce a bias, 
by altering the clearance of the two peptides [53].
2.3.3. Troponin
Some markers of cardiac injury have been also proposed as cardiorenal biomarkers, such as 
troponin. It is known that when acute myocardial injury occurs, myocytes release cardiac tro-
ponin (T and I) within 3–12 h; a mean peak in its circulating values is achieved after 12–48 h, 
returning to baseline levels in 5–14 days. Asymptomatic subjects with increased troponins 
have a threefold risk in all-cause and CV mortality [54]. A recent meta-analysis reported a 
close association between increased levels of cardiac troponins and increased risk of coronary 
artery disease in CKD patients [55]. According to National Academy of Clinical Biochemistry 
Laboratory Medicine Practice guidelines, a change of ≥20% in cardiac troponins, in ESRD 
patients, is a good marker for acute coronary syndrome [56].
Reinforcing the link between cardiac damage and ESRD development, it was reported that 
the levels of cardiac troponin T and NT-proBNP are independent predictors of ESRD risk in 
the general population, as well as, in subjects with diabetes mellitus and anemia [57].
2.3.4. Adiponectin and leptin
In both CKD and CVD patients, an abnormal lipid profile is common, as well as an altered 
production of adipokines. Adiponectin and leptin have been also proposed as cardiorenal 
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biomarkers. High levels of adiponectin and leptin are common in CKD patients; however, this 
change in adiponectin has been associated with increased risk of mortality; hyperleptinemia 
has been associated with several CVD risk factors, such as inflammation, IR, protein energy 
wasting, and with progression of CKD, by favoring hypertension and fibrosis [58].
2.3.5. Matrix-metalloproteases
Renal fibrosis seems to progress through several steps: inflammation, activation and transfor-
mation of fibroblast to myofibroblast, matrix deposition and fibrosis. Matrix-metalloproteases 
(MMP) have an important role in fibrosis and are also vital in angiogenesis and vascular 
remodeling; their activation may alter the architecture of the atherosclerotic plaque, partici-
pating in plaque rupture processes. In CKD, MMP-2 showed a positive and reliable asso-
ciation with carotid intima-media thickness [59]. However, further studies are needed to 
investigate the association of MMPs and other matrix-related markers, such as galectin-3 and 
ST2, with CVD in CKD patients. Galectin-3, secreted by macrophages and known for its role 
in mediating cardiac fibrosis and inflammation, was approved by the US Food and Drug 
Administration as a new biomarker for HF risk [60].
2.3.6. CRP and PTX3
A persistent mild-to-moderate inflammation is common in CKD patients and enhanced in 
ESRD patients. Inflammation is able to amplify other common features, as oxidative stress, 
atherosclerosis, vascular calcification, depression and protein energy wasting, acting as a cat-
alyst of risk factors for ESRD. Several studies showed the association between biomarkers of 
systemic inflammation, as CRP, IL-6, tumor necrosis factor-alpha and fibrinogen, with lower 
kidney function [61]. Moreover, several pro-inflammatory cytokines have been associated 
with a higher risk for CV events and for mortality.
According to Dialysis Outcomes and Practice Patterns Study (DOPPS), III study, CRP mea-
surement is increasing in most countries [62]. This study showed that CRP monitoring within 
a dialysis facility is significantly associated with a lower CV mortality, suggesting that this 
practice may benefit patient’s outcome. Indeed, an increase in CRP, showing worsening of 
inflammation, would trigger the search for underlying causes, allowing a more rapid clinical 
intervention and a better outcome. This study also showed that the relation of CRP to mortal-
ity was independent of other common inflammatory markers.
Pentraxin 3 (PTX3), produced by resident and innate immunity cells in peripheral tis-
sues, increases rapidly within the primary local of activation, triggering the inflamma-
tory response. Thus, while CRP is produced by hepatocytes, PTX3 is synthesized at the 
site of inflammation. It increases as renal function declines and predicts CV and overall 
mortality risk in CKD patients. PTX3 also plays regulatory functions in angiogenesis, 
atherosclerosis, apoptotic cell clearance and tissue repair [63]. The rapid increase in PTX3 
expression in vascular endothelial cells, following an inflammatory stimulus, showed that 
it could be a useful marker for vascular pathology. Indeed, PTX3 seems to be a power-
ful marker of inflammation and a good biomarker for development and progression of 
atherosclerosis.
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2.3.7. Growth differentiation factor 15
Growth differentiation factor 15 (GDF-15) has been also associated with inflammation, as well 
as with cancer, aging, diabetes mellitus and atherosclerosis, emerging as strong risk factor 
for mortality in individuals with existing CVD. High GDF-15 levels also reflect progressive 
kidney dysfunction and poor outcome in CKD patients [64].
2.3.8. Neutrophil gelatinase-associated lipocalin
The activation of inflammatory cells is accompanied by the release of several pro-inflamma-
tory cytokines that have been associated with a higher risk for CV events and for mortality, 
in CKD patients. Neutrophil activation is accompanied by metabolic burst with production 
of oxygen metabolites and release of granule content, contributing to oxidative stress and to 
the inflammatory response. Neutrophil gelatinase-associated lipocalin (NGAL) is a marker 
of neutrophil activation that appears as an early biomarker of acute kidney injury. This gly-
coprotein has been also related to atherosclerosis and CVD [47]. Urinary NGAL levels seem 
to be independently associated with ischemic atherosclerotic events [65]. Furuya et al. [66] 
reported that NGAL levels were higher in HD patients with CVD, when compared to patients 
without CVD.
2.3.9. Kidney injury molecule-1
Kidney injury molecule-1 (KIM-1) is another biomarker of kidney injury. After proximal tubu-
lar injury, the transmembrane protein KIM-1 is highly upregulated. Sabbisetti et al. reported 
that KIM-1 levels are elevated in CKD patients, and in patients with type 1 diabetes mellitus 
and proteinuria, the circulating levels of KIM-1 predict the loss of estimated GFR (eGFR) and 
the risk for ESRD [67]. The Chronic Renal Insufficiency Cohort (CRIC) study reported that 
CKD patients in the highest two quintiles of KIM-1/creatinine (Cr) values had a higher risk 
of heart failure, as compared to those in the lowest quintile. Moreover, the ratio KIM-1/Cr 
was independently associated with atherosclerotic CVD events, and the ratios KIM-1/Cr and 
NGAL/Cr were associated with all-cause death [68].
2.3.10. Other markers
Other early biomarkers of renal dysfunction, as liver-type fatty acid binding protein and cys-
tatin C, might be useful in the early detection of renal involvement in CVD patients. Increased 
levels of cystatin-C in CKD patients have been associated with CVD risk, as well as with all-
cause mortality [69].
Considering that both CKD and CVD have oxidative stress as a common feature, some oxida-
tive stress biomarkers, as malondialdehyde, oxLDL, advanced glycation end-products, have 
been proposed as potential renocardiovascular markers of risk.
Uric acid has also emerged as a risk factor for progression of CKD that might be also linked 
to CVD risk; however, it is not clear whether hyperuricemia plays a causative role in CKD 
progression or is only a biomarker of kidney dysfunction [70].
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Asymmetric dimethylarginine (ADMA), an amino acid found in tissues and cells, acts as an 
endogenous inhibitor of nitric oxide synthase and has emerged as a biomarker of endothelial 
dysfunction, CVD risk, and CKD outcome [71].
The disturbances in mineral metabolism observed in CKD patients play a crucial role in the 
development of CVD, and some biomarkers have been proposed as potential renocardiovas-
cular biomarkers, such as fibroblast growth factor (FGF)-23, fetuin A, osteoprotegerin, vitamin 
D and parathyroid hormone. FGF-23 seems to be a promisor CVD biomarker both in subjects 
without renal dysfunction and in CKD and ESRD patients, especially in the last ones [47]. In a 
prospective cohort of 3860 patients with CKD stages 2–4, enhanced FGF-23 levels were associ-
ated with higher risk of CVD, especially with CHF [72]. FGF-23 seems to regulate the produc-
tion of fetuin-A, a glycoprotein with anti-calcification activity [73]. Considering the crosstalk 
between these two proteins, both appear as promising renocardiovascular biomarkers.
Progressive loss of kidney function is linked to a reduction in the production of vitamin D and 
to a disturbance in serum calcium and phosphorus balance that have been associated with 
poor CKD outcome and to increased risk for CVD events and mortality [74].
Fibrinogen, a glycoprotein involved in blood clot formation, is a marker of CVD in the general 
population and was also pointed as a marker of CV and all-cause mortality in ESRD patients [69].
The relationship between CV events and CKD/ESRD is complex and poorly understood. A 
better understanding of this relationship might be helpful for the validation of these potential 
renocardiovascular biomarkers and, eventually, for the identification of new biomarkers. The 
definition of a biomarker or a panel of biomarkers to evaluate CVD risk in CKD patients will 
be a great achievement. Meanwhile, further studies are needed to confirm if the biomarkers 
that have emerged are good and reliable biomarkers of CV risk in CKD.
3. Hemodialysis versus online-hemodiafiltration
Advanced age and comorbid conditions at starting dialysis, as well as efficacy and quality 
of renal replacement therapy, are some of the factors that affect dialysis patient’s mortality. 
Dialysis techniques, applied for more than 50 years, have clearly improved over the last few 
years; however, despite refinements of dialysis therapy, both CV and all-cause mortality rates 
in ESRD patients treated with conventional HD remain significant.
The introduction of online-hemodiafiltration (OL-HDF), by combining HD and hemofiltration 
(HF) modalities, was believed to improve patient’s outcome, namely their QoL, morbidity 
and mortality. HDF combines diffusive and convective transport through a high-flux dialysis 
membrane. The convective transport is achieved by filtering a volume of plasma water sub-
stantially in excess of that needed to achieve dry weight and, at the same time, by infusing a 
sterile substitution fluid directly into the patient’s bloodstream. The substitution fluid is pre-
pared online and can be administered before (predilution) or after (postdilution) the dialyzer.
It has been proposed that OL-HDF increases the dialysis efficacy, by removing uremic toxins 
with higher molecular weight up to middle and large solutes; ameliorates the clinical tolerance 
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to HD sessions; improves patient’s HRQoL; and improves the biocompatibility of the dialysis 
system, through the combination of the use of high flux synthetic membranes with ultrapure 
dialysis fluid purity [75, 76].
Some studies comparing cost-effectiveness of OL-HDF and HD reported that HD is more 
cost-effective; however, a recent analysis by Ramponi et al. [77] showed that OL-HDF is as 
cost-effective as high-flux HD. An advantage over high-flux HD is the substantial effect of 
OL-HDF on the improvement of patient’s satisfaction and QoL [78]. Another advantage of 
OL-HDF over HD procedure is its higher biocompatibility and dialysis efficacy that appears 
to improve the outcome of ESRD patients. Indeed, by reducing the inflammatory response 
and the associated complications, it would, probably, contribute to reduce the high morbidity 
and mortality of ESRD patients [75, 76, 79, 80]. For instance, OL-HDF showed more favor-
able acute and short-term effects than conventional HD on markers of endothelial dysfunc-
tion, namely on flow-mediated dilatation of the brachial artery, soluble endothelial protein C 
receptor and soluble thrombomodulin [81].
A summary of some studies comparing long- or medium-term effects of OL-HDF and HD is 
presented in Table 1.
A study performed in 2006 that enrolled 2165 patients, stratified into low- and high-flux HD and 
low- and high-efficiency HDF groups, reported that high-efficiency HDF patients presented a 
significant 35% lower mortality risk than those receiving low-flux HD; the authors also reported 
that HDF may improve patient’s survival independently of (a higher) dialysis dose [82].
The prospective and observational RISCAVID study also reported a better survival with 
OL-HDF therapy versus HD [83]. A retrospective study reported that ESRD patients predomi-
nantly treated with OL-HDF showed also a better survival, as compared to patients treated 
with high-flux HD therapy; nonetheless, according to the authors mortality benefit with HDF 
needs confirmation; no benefits were detected for anemia management, nutrition, mineral 
metabolism and blood pressure control [84].
In the Grooteman study [85], the CONvective TRAnsport STudy (CONTRAST), 714 chronic 
HD patients were evaluated, 358 on OL-HDF and 356 on low-flux HD. After a 3-year follow-
up study (range 0.4–6.6 years), no significant beneficial differences in all-cause mortality and 
CV events were found between the two groups. Further analysis suggested a possible benefit 
for survival of patients under high-volume HD treatment in the group of patients with the 
highest delivered convection volume (upper tertile >21.95 L); mortality in these patients was 
considerably lower than in those randomized to low-flux hemodialysis.
In a multicenter, open-label, randomized controlled trial [86], the ESHOL or Catalonian 
hemodiafiltration study, 906 chronic HD patients were enrolled in the study; 456 switched 
to high-efficiency postdilution OL-HDF and 405 continued on HD; a reduction in all-cause 
mortality was observed for OL-HDF, when compared to conventional HD treatment. Patients 
assigned to OL-HDF, as compared to HD, had a 30% lower risk of all-cause mortality, a 33% 
lower risk of CV mortality, and a 55% lower risk of infection-related mortality. Moreover, the 
dialysis sessions complicated by hypotension and all-cause hospitalization presented lower 
incidence rates in patients receiving OL-HDF. A reanalysis of the ESHOL study showed that 
in prevalent patients, postdilution OL-HDF, versus HD, reduced all-cause mortality [87].
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Authors Year Study length Patients Major findings
Canaud et al. [82] 2006 3 y n = 2165 HDF may improve patient 
survival independently of  
(a higher) dialysis dose
Panichi et al. [83] 2008 30 m n = 757 HDF was associated with an 
improved cumulative survival, 
independently of dialysis dose
Vilar et al. [84] 2009 Retrospective study 
(18-y period)
n = 858 No benefits of HDF over 
high-flux HD for anemia 
management, nutrition, mineral 
metabolism and BP control; 
mortality benefit with HDF 
needs confirmation
Grooteman et al. [85] 2012 3 y (mean) n = 714 (358: OL-HDF; 
356: HD)
No beneficial effect of HDF 
on all-cause mortality and CV 
events compared with low-flux 
HD; possible survival benefit for 
HDF (requires confirmation)
Maduell et al. [86] 2013 1.91 ± 1.10 y n = 906 (456: OL-HDF; 
450: HD)
High-efficiency OL-HDF 
reduces all-cause mortality, 
compared with conventional HD
Ok et al. [88] 2013 22.7 ± 10.9 m n = 782 All-cause mortality and nonfatal 
CV event rate were similar for 
OL-HDF and high-flux HD 
groups; in a post hoc analysis, 
OL-HDF treatment with 
substitution volumes over 17.4 L 
was associated with better CV 
and overall survival
van der Weerd et al. [89] 2014 12 m n = 714 Compared to low-flux HD, 
OL-HDF treatment did not 
decrease ESA resistance
Mostovaya et al. [90] 2014 4 y n = 342 OL-HDF did not affect changes 
in LVM, VEF or PWV over time, 
compared with HD
Siriopol et al. [91] 2015 Retrospective study 
(3 y)
n = 1546 (1322: HD; 
224: HDF); n = 2447 
(2181: HD; 266: HDF)
HDF reduced all-cause mortality 
in incident and prevalent 
patients, even after correction 
for different confounders
Mercadal et al. [92] 2016 1.95 y (median) n = 28,407 (5526 used 
HDF for a median of 
1.2 years; 2254 of them 
used HDF exclusively)
HDF treatment was associated 
with better survival
Smith et al. [93] 2016 8 w of HD followed 
by 8 w of OL-HDF 
(or vice versa)
n = 100 Similar posttreatment recovery 
time and HRQoL scores
BP, blood pressure; CV, cardiovascular; ESA, erythropoiesis-stimulating agents; HRQoL, health-related quality of 
life; LVM, left ventricular mass; OL, online; PWV, pulse-wave velocity; VEF, ventricular ejection fraction; w, week; 
m, months; y, year.
Table 1. Some of hemodialysis (HD) versus hemodiafiltration (HDF) studies.
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The Turkish OL-HDF Study [88], a follow-up study of nearly 2 years, found that the preva-
lence of death from any cause and of nonfatal CV events was similar for OL-HDF and for 
high-flux HD groups; CV and overall survival, hospitalization rate and number of hypoten-
sive episodes were also similar; however, a subgroup of OL-HDF patients treated with sub-
stitution volumes over 17.4 L, above the median convective volume, presented a better CV 
and overall survival, when compared to HD patients. It was also reported that small solute 
clearance was higher in OL-HDF group and, in spite of the similar hemoglobin levels in the 
two groups, the prescribed dose of EPO and the erythropoietin resistance index were signifi-
cantly lower in OL-HDF group. The increase in EPO response seems to be due to the higher 
clearance of middle-sized molecules and to the improvement in the microbiological quality 
of fluids used in OL-HDF procedures that may contribute to reduce systemic inflammation. 
In opposition, the trial CONTRAST [89], a 12-month follow-up study of 714 patients random-
ized to either treatment with online postdilution HDF or continuation of low-flux HD showed 
that OL-HDF treatment did not decrease the index of resistance to erythropoiesis-stimulating 
agents, when compared to HD treatment.
Cardiovascular parameters, as left ventricular mass, ventricular ejection fraction and pulse-
wave velocity, are altered in ESRD patients and are usually associated with CV mortality. A 
study by Mostovaya et al. [90] showed that OL-HDF did not improve these CV parameters 
over time, when compared to HD therapy.
A retrospective analysis by Siriopol et al. [91] on Romanian dialyzed population, using the 
European Clinical Database (EUCLID) Fresenius Medical Care Database, showed that HDF 
reduced all-cause mortality in incident and prevalent patients, even after correction for differ-
ent confounders; however, other unmeasured confounders could have influenced their final 
results [91].
Analysis of data from the French National Renal Epidemiology and Information Network 
(REIN) registry, enrolling 28,407 patients (5526 switched for HDF; 2254 were only treated 
with HDF and the others were treated with HD), reported that patients exclusively on HDF 
presented the best survival [92].
In a recent randomized, single-blind, crossover trial, HD and HDF patients showed similar 
posttreatment recovery time and HRQoL [93].
A systematic review conducted in 2006, analyzed 20 trials including 657 patients, reported 
inconclusive data concerning the improvement of convective therapies (HDF, hemofiltration 
and acetate-free biofiltration), versus HD, on mortality, dialysis-related hypotension and hos-
pitalization [94].
A 2014 meta-analysis of 16 randomized trials [95] (three large trials were already referred 
[85, 86, 88]), including 3220 ESRD patients, focused and compared the effect of convective 
modalities (hemofiltration and HDF), with standard dialysis. This meta-analysis demon-
strated that HDF did not alter significantly clinical CV outcome rates. Indeed, the effect of 
convective modalities on clinical CV outcome was not statistically different, when compared 
to either low-flux or high-flux HD treatment. Moreover, convective modalities, as compared 
to standard dialysis, showed no different all-cause mortality rates; in addition, mortality 
rate was independent of the type of convective modality. It was also reported that systolic 
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blood pressure, at end of the treatments, was similar for convective modalities and standard 
HD. Dialysis adequacy was also similar, although there were evidences of heterogeneity 
within data from the different studies. The convective modalities seem to reduce significantly 
postdialysis serum levels of β
2
-microglobulin. HRQoL was evaluated in three trials, and no 
significant differences in physical symptoms domain scores were observed between convec-
tive modalities and standard dialysis.
In opposition, another meta-analysis reported in 2014 [96], including six randomized con-
trolled trials, comparing online postdilution HDF with HD treatment, showed a reduction 
in mortality risk and CV death for patients treated with online postdilution HDF; moreover, 
when considering the three largest randomized controlled trials, an inverse relation between 
convection volume magnitude and mortality risk was observed. The authors highlighted that 
the randomized controlled trials analyzed in this meta-analysis contained several potential 
risks of bias that may over- or underestimate the effects.
In 2015, another systematic review comparing convective modalities with HD therapy 
included a higher number of studies and ESRD patients (40 studies, 4137 patients) [97]. This 
meta-analysis showed that convective therapies may contribute to reduce CV mortality, but 
not all-cause mortality; the benefits on CVD events, hospitalization and QoL versus HD, were 
once again not conclusive [97].
Based on individual participant data of four large multicenter randomized controlled trials, 
it was recently reported (2017) that OL-HDF, compared to conventional HD, reduces the risk 
of mortality in ESRD patients [98]. Using the same individual participant data, Nubé et al. 
[99] conducted a study to investigate whether the reduction on mortality risk associated with 
HDF resulted from a reduction in CVD events and which type of CV events explained that 
reduction. A decrease in fatal ischemic heart disease and congestion appeared to underlie the 
positive effect of OL-HDF on CV and all-cause mortality.
The French Convective versus Hemodialysis in Elderly (FRENCHIE) study aimed to com-
pare intradialytic tolerance of OL-HDF versus high-flux HD [100]. A significantly lower 
occurrence of adverse events, with fewer episodes of intradialytic symptomatic hypo-
tension and muscle cramps, was found for OL-HDF patients; moreover, serum albumin 
values were similar, but an improvement in metabolic bone disease biomarkers and in 
β
2
-microglobulin levels was found [100]. HRQoL, morbidity and mortality were similar for 
both treatments.
In summary, the improvement on all-cause mortality and on CVD events for OL-HDF treat-
ment is still controversial, and therefore, it is not entirely clear if OL-HDF is, actually, a better 
alternative to standard HD.
4. Conclusions remarks
ESRD patients present high mortality and incidence of CV events. The occurrence of CVD 
events appear as a consequence of the high prevalence of traditional and non-traditional CV 
risk factors in these patients.
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OL-HDF, an alternative to standard dialysis, was introduced as a better alternative to conven-
tional dialysis. Nevertheless, convective modalities benefits versus standard dialysis, in what 
concern CV outcome or all-cause mortality remain questionable. Regarding clearance of small 
molecules, no evidence exists of a superior effect [95], though convective modalities appear to 
diminish the incidence of symptomatic hypotension and to enhance middle-molecular clear-
ance (as assessed by β
2
-microglobulin). One possibility is that the delivered dose of HDF 
was not sufficient, considering that in two of the larger trials [85, 88], a positive association 
between higher convective volume replacement and better relative outcomes was observed. 
Indeed, the importance of convective volume to improve survival of OL-HDF patients has 
been highlighted [101]. Higher convection volumes in OL-HDF were associated with higher 
patient’s survival; however, results varied across different ways of standardization for body 
size, suggesting that further studies should consider body size [102]. Apparently, when ade-
quate convection volumes are used, OL-HDF reduces all-cause and CV mortality risk.
Data from clinical trials and meta-analyses are controversial and not conclusive. It is not clear 
if OL-HDF is really a reliable alternative to HD in what concerns all-cause mortality and 
CVD events. We must consider that the studies about these issues are still too small or too 
short in duration, to detect a true benefit. Thus, further trials, with larger number of patients, 
involving longer follow-up periods and, eventually, with patients receiving higher volume 
replacement, to increase the precision of the survival analyses and to evaluate the real impact 
of OL-HDF procedure in mortality and CV outcome of ESRD patients are necessary.
Acknowledgements
This work received financial support from FCT/MEC through national funds and cofinanced 
by FEDER, under the Partnership Agreement PT2020 (UID/MULTI/04378/2013-POCI/01/0145/
FEDER/007728) and North Portugal Regional Coordination and Development Commission 
(CCDR-N)/NORTE2020/Portugal 2020 (Norte-01-0145-FEDER-000024).
Author details
Susana Coimbra1,2, Maria do Sameiro Faria3,4, Vasco Miranda3, Luís Belo5 and  
Alice Santos-Silva5*
*Address all correspondence to: assilva@ff.up.pt
1 CESPU, Institute of Research and Advanced Training in Health Sciences and Technologies 
(IINFACTS), Gandra-PRD, Porto, Portugal
2 UCIBIO\REQUIMTE, Porto, Portugal
3 NephroCare Hemodialysis Clinic, Maia, Portugal
4 Unit of Pediatric Nephrology, Centro Materno Infantil do Norte, Porto, Portugal
5 UCIBIO\REQUIMTE, Department of Biological Sciences, Laboratory of Biochemistry, 
Faculty of Pharmacy, University of Porto, Porto, Portugal
Aspects in Dialysis124
References
[1] Weiner DE. Causes and consequences of chronic kidney disease: Implications for man-
aged health care. Journal of Managed Care Pharmacy. 2007;13:S1-S9
[2] Chen RA, Scott S, Mattern WD, Mohini R, Nissenson AR. The case for disease manage-
ment in chronic kidney disease. Disease Management. 2006;9:86-92
[3] AIHW. Projections of the Prevalence of Treated End-Stage Kidney Disease in Australia 
2012-2020. Canberra: AIHW. p. 2014
[4] Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? Nephrology 
Dialysis Transplantation. 2002;17:33-38
[5] Canaud B. Online hemodiafiltration. Technical options and best clinical practices. 
Contribution to Nephrology. 2007;158:110-122
[6] Rayner HC, Pisoni RL, Bommer J, et al. Mortality and hospitalization in haemodialysis 
patients in five European countries: Results from the Dialysis Outcomes and Practice 
Patterns Study (DOPPS). Nephrology Dialysis Transplantation. 2004;19:108-120
[7] Foley RN, Hakim RM. Why is the mortality of dialysis patients in the United States 
much higher than the rest of the world? Journal of the American Society of Nephrology. 
2009;20:1432-1435
[8] Yoshino M, Kuhlmann MK, Kotanko P, et al. International differences in dialysis mor-
tality reflect background general population atherosclerotic cardiovascular mortality. 
Journal of the American Society of Nephrology. 2006;17:3510-3519
[9] USRDS. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-
Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, 
National Institute of Diabetes and Digestive and Kidney Diseases; 2013
[10] Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albumin-
uria for prediction of cardiovascular outcomes: A collaborative meta-analysis of indi-
vidual participant data. The Lancet Diabetes and Endocrinology. 2015;3:514-525
[11] Salinero-Fort MA, San Andres-Rebollo FJ, de Burgos-Lunar C et al. Cardiovascular and 
all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort 
Study: Association with chronic kidney disease. Journal of Diabetes Complications. 
2016;30(2):227-36. DOI: 10.1016/j.jdiacomp.2015.10.007. Epub 2015 Oct 21
[12] Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: A 
consensus statement on the diagnosis of heart failure with normal left ventricular ejec-
tion fraction by the Heart Failure and Echocardiography Associations of the European 
Society of Cardiology. European Heart Journal. 2007;28:2539-2550
[13] Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic 
kidney disease and risk of major cardiovascular disease and non-vascular mortality: 
Prospective population based cohort study. BMJ. 2010;341:c4986
[14] Matsushita K, Ballew SH, Coresh J. Influence of chronic kidney disease on cardiac struc-
ture and function. Current Hypertension Reports. 2015;17:581
Cardiovascular Risk Factors in End-Stage Renal Disease Patients: The Impact of Conventional...
http://dx.doi.org/10.5772/intechopen.70465
125
[15] Salinero-Fort MA, San Andres-Rebollo FJ, de Burgos-Lunar C, et al. Cardiovascular and 
all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort 
Study: Association with chronic kidney disease. Journal of Diabetes Complications. 
2016;30:227-236
[16] Huang M, Matsushita K, Sang Y, Ballew SH, Astor BC, Coresh J. Association of kidney 
function and albuminuria with prevalent and incident hypertension: The Atherosclerosis 
Risk in Communities (ARIC) study. The American Journal of Kidney Diseases. 
2015;65:58-66
[17] Zbroch E, Malyszko J, Zorawski MJ, Mysliwiec M. Kidney and hypertension: Is there a 
place for renalase? Polskie Archiwum Medycyny Wewnȩtrznej. 2012;122:174-179
[18] Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kid-
ney disease: Implications for the pathophysiology of atherosclerosis. Journal of 
Atherosclerosis and Thrombosis. 2013;20:123-133
[19] Moradi H, Vaziri ND, Kashyap ML, Said HM, Kalantar-Zadeh K. Role of HDL dys-
function in end-stage renal disease: A double-edged sword. Journal of Renal Nutrition. 
2013;23:203-206
[20] Sonmez A, Yilmaz MI, Saglam M, et al. The role of plasma triglyceride/high-density 
lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney dis-
ease. Lipids Health Disease. 2015;14:29
[21] Ribeiro S, Faria Mdo S, Silva G, et al. Oxidized low-density lipoprotein and lipoprotein(a) 
levels in chronic kidney disease patients under hemodialysis: Influence of adiponec-
tin and of a polymorphism in the apolipoprotein(a) gene. Hemodialysis International. 
2012;16:481-490
[22] Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and 
kidney disease: A systematic review and meta-analysis. Kidney International. 2008;73: 
19-33
[23] Stenvinkel P, Zoccali C, Ikizler TA. Obesity in CKD—What should nephrologists know? 
Journal of the American Society of Nephrology. 2013;24:1727-1736
[24] Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al. Association of morbid obesity and 
weight change over time with cardiovascular survival in hemodialysis population. The 
American Journal of Kidney Diseases. 2005;46:489-500
[25] Stack AG, Murthy BV. Cigarette use and cardiovascular risk in chronic kidney disease: 
An unappreciated modifiable lifestyle risk factor. Seminars in Dialysis. 2010;23:298-305
[26] Muslimovic A, Rasic S, Tulumovic D, Hasanspahic S, Rebic D. Inflammatory markers 
and pro-coagulants in chronic renal disease stages 1-4. Medical Archives. 2015;69:307-310
[27] Lee BT, Ahmed FA, Hamm LL, et al. Association of C-reactive protein, tumor necro-
sis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrology. 
2015;16:77
Aspects in Dialysis126
[28] do Sameiro-Faria M, Ribeiro S, Costa E, et al. Risk factors for mortality in hemodialysis 
patients: Two-year follow-up study. Disease Markers. 2013;35:791-798
[29] Piroddi M, Depunzio I, Calabrese V, et al. Oxidatively-modified and glycated proteins 
as candidate pro-inflammatory toxins in uremia and dialysis patients. Amino Acids. 
2007;32:573-592
[30] Xu G, Luo K, Liu H, Huang T, Fang X, Tu W. The progress of inflammation and oxidative 
stress in patients with chronic kidney disease. Renal Failure. 2015;37:45-49
[31] Ramirez R, Martin-Malo A, Aljama P. Inflammation and hemodiafiltration. Contribution 
to Nephrology. 2007;158:210-215
[32] Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease—What have we 
learned in 10 years? Seminars in Dialysis. 2010;23:498-509
[33] Cobo G, Qureshi AR, Lindholm B, Stenvinkel P. C-reactive protein: Repeated measure-
ments will improve dialysis patient care. Seminars in Dialysis. 2016;29:7-14
[34] Bowry SK, Gatti E. Impact of hemodialysis therapy on anemia of chronic kidney disease: 
The potential mechanisms. Blood Purification. 2011;32:210-219
[35] Wagner M, Ashby DR, Kurtz C, et al. Hepcidin-25 in diabetic chronic kidney dis-
ease is predictive for mortality and progression to end stage renal disease. PloS One. 
2015;10:e0123072
[36] Costa E, Rocha S, Rocha-Pereira P, et al. Band 3 profile as a marker of erythrocyte changes 
in chronic kidney disease patients. The Open Clinical Chemistry Journal. 2008;1:57-63
[37] Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress 
in end-stage renal disease: An emerging threat to patient outcome. Nephrology Dialysis 
Transplantation. 2003;18:1272-1280
[38] Lucchi L, Iannone A, Bergamini S, et al. Comparison between hydroperoxides and 
malondialdehyde as markers of acute oxidative injury during hemodialysis. Artificial 
Organs. 2005;29:832-837
[39] Zhou Q, Wu S, Jiang J, et al. Accumulation of circulating advanced oxidation protein 
products is an independent risk factor for ischaemic heart disease in maintenance hae-
modialysis patients. Nephrology (Carlton, Vic.). 2012;17:642-649
[40] Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxy-
gen species in end-stage renal disease patients: A potential component of hemodialysis-
associated inflammation. Hemodialysis International. 2005;9:37-46
[41] Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study dem-
onstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney 
International. 2007;71:1036-1043
[42] Liao MT, Sung CC, Hung KC, Wu CC, Lo L, Lu KC. Insulin resistance in patients with 
chronic kidney disease. Journal of Biomedicine and Biotechnology. 2012;2012:691369
Cardiovascular Risk Factors in End-Stage Renal Disease Patients: The Impact of Conventional...
http://dx.doi.org/10.5772/intechopen.70465
127
[43] Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: Assessing the 
current evidence linking outcomes with treatment adherence. BMC Nephrology. 
2013;14:153
[44] Chen J, Budoff MJ, Reilly MP, et al. Coronary artery calcification and risk of cardiovas-
cular disease and death among patients with chronic kidney disease. JAMA Cardiology. 
2017;2:635-643
[45] Chen J, Mohler ER, Xie D, et al. Traditional and non-traditional risk factors for incident 
peripheral arterial disease among patients with chronic kidney disease. Nephrology 
Dialysis Transplantation. 2016;31:1145-1151
[46] Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: Report from the 
consensus conference of the acute dialysis quality initiative. European Heart Journal. 
2010;31:703-711
[47] Niizuma S, Iwanaga Y, Yahata T, Miyazaki S. Renocardiovascular biomarkers: From 
the perspective of managing chronic kidney disease and cardiovascular disease. Front 
Cardiovascular Medicine. 2017;4:10
[48] Tang WH, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry 
Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker test-
ing in heart failure. Circulation. 2007;116:e99-e109
[49] Wang AY, Lam CW, CM Y, et al. N-terminal pro-brain natriuretic peptide: An indepen-
dent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascu-
lar outcomes in chronic peritoneal dialysis patients. Journal of the American Society of 
Nephrology. 2007;18:321-330
[50] Lombardi C, Gargioni S, Venturi S, Zoccali P, Canonica GW, Passalacqua G. Controlled 
study of pre-seasonal immunotherapy with grass pollen extract in tablets: Effect on bron-
chial hyper-reactivity. Journal of Investigational Allergology and Clinical Immunology. 
2001;11:41-45
[51] Riphagen IJ, Boertien WE, Alkhalaf A, et al. Copeptin, a surrogate marker for arginine 
vasopressin, is associated with cardiovascular and all-cause mortality in patients with 
type 2 diabetes (ZODIAC-31). Diabetes Care. 2013;36:3201-3207
[52] Fenske W, Wanner C, Allolio B, et al. Copeptin levels associate with cardiovascular 
events in patients with ESRD and type 2 diabetes mellitus. Journal of the American 
Society of Nephrology. 2011;22:782-790
[53] Roussel R, Fezeu L, Marre M, et al. Comparison between copeptin and vasopressin in a 
population from the community and in people with chronic kidney disease. Journal of 
Clinical Endocrinology and Metabolism. 2014;99:4656-4663
[54] Sze J, Mooney J, Barzi F, Hillis GS, Chow CK. Cardiac troponin and its relationship to 
cardiovascular outcomes in community populations—A systematic review and meta-
analysis. Heart Lung Circulation. 2016;25:217-228
Aspects in Dialysis128
[55] Michos ED, Wilson LM, Yeh HC, et al. Prognostic value of cardiac troponin in patients 
with chronic kidney disease without suspected acute coronary syndrome: A systematic 
review and meta-analysis. Annals Internal Medicine. 2014;161:491-501
[56] AH W, Jaffe AS, Apple FS, et al. National Academy of Clinical Biochemistry laboratory 
medicine practice guidelines: Use of cardiac troponin and B-type natriuretic peptide or 
N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syn-
dromes and heart failure. Clinical Chemistry. 2007;53:2086-2096
[57] Desai AS, Toto R, Jarolim P, et al. Association between cardiac biomarkers and the 
development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. The 
American Journal of Kidney Diseases. 2011;58:717-728
[58] Alix PM, Guebre-Egziabher F, Soulage CO. Leptin as an uremic toxin: Deleterious role 
of leptin in chronic kidney disease. Biochimie. 2014;105:12-21
[59] Kousios A, Kouis P, Panayiotou AG. Matrix metalloproteinases and subclinical ath-
erosclerosis in chronic kidney disease: A systematic review. International Journal of 
Nephrology. 2016;2016:9498013
[60] Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of 
heart failure: A report of the American College of Cardiology Foundation/American 
Heart Association Task Force on Practice Guidelines. Journal of American College of 
Cardiology. 2013, 2013;62:e147-e239
[61] Lin J, FB H, Rimm EB, Rifai N, Curhan GC. The association of serum lipids and inflam-
matory biomarkers with renal function in men with type II diabetes mellitus. Kidney 
International. 2006;69:336-342
[62] Kawaguchi T, Tong L, Robinson BM, et al. C-reactive protein and mortality in hemodi-
alysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron 
Clinical Practice. 2011;117:c167-c178
[63] Witasp A, Ryden M, Carrero JJ, et al. Elevated circulating levels and tissue expression of 
pentraxin 3 in uremia: A reflection of endothelial dysfunction. PloS One. 2013;8:e63493
[64] Ho JE, Hwang SJ, Wollert KC, et al. Biomarkers of cardiovascular stress and incident 
chronic kidney disease. Clinical Chemical. 2013;59:1613-1620
[65] Liu KD, Yang W, Go AS, et al. Urine neutrophil gelatinase-associated lipocalin and risk of 
cardiovascular disease and death in CKD: Results from the Chronic Renal Insufficiency 
Cohort (CRIC) study. The American Journal of Kidney Diseases. 2015;65:267-274
[66] Furuya F, Shimura H, Yokomichi H, et al. Neutrophil gelatinase-associated lipocalin lev-
els associated with cardiovascular disease in chronic kidney disease patients. Clinical 
and Experimental Nephrology. 2014;18:778-783
[67] Sabbisetti VS, Waikar SS, Antoine DJ, et al. Blood kidney injury molecule-1 is a bio-
marker of acute and chronic kidney injury and predicts progression to ESRD in type I 
diabetes. Journal of the American Society of Nephrology. 2014;25:2177-2186
Cardiovascular Risk Factors in End-Stage Renal Disease Patients: The Impact of Conventional...
http://dx.doi.org/10.5772/intechopen.70465
129
[68] Park M, Hsu CY, Go AS, et al. Urine kidney injury biomarkers and risks of cardiovascu-
lar disease events and all-cause death: The CRIC study. Clinical Journal of the American 
Society of Nephrology. 2017;12:761-771
[69] Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers 
in chronic kidney disease: A review. Kidney International. 2011;80:806-821
[70] Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal out-
comes: A systematic review and meta-analysis. Nephrology Dialysis Transplantation. 
2014;29:406-413
[71] Raptis V, Kapoulas S, Grekas D. Role of asymmetrical dimethylarginine in the progres-
sion of renal disease. Nephrology (Carlton, Vic.). 2013;18:11-21
[72] Scialla JJ, Xie H, Rahman M, et al. Fibroblast growth factor-23 and cardiovascular events 
in CKD. Journal of the American Society of Nephrology. 2014;25:349-360
[73] Mattinzoli D, Rastaldi MP, Ikehata M, et al. FGF23-regulated production of Fetuin-A 
(AHSG) in osteocytes. Bone. 2016;83:35-47
[74] Bover J, Cozzolino M. Mineral and bone disorders in chronic kidney disease and end-
stage renal disease patients: New insights into vitamin D receptor activation. Kidney 
International. 2011;1(Suppl):122-129
[75] Locatelli F, Manzoni C, Vigano S, Cavalli A, Di Filippo S. Hemodiafiltration—State of the 
art. Contribution to Nephrology. 2011;168:5-18
[76] den Hoedt CH, Mazairac AH, van den Dorpel MA, Grooteman MP, Blankestijn PJ. Effect 
of hemodiafiltration on mortality, inflammation and quality of life. Contribution to 
Nephrology. 2011;168:39-52
[77] Ramponi F, Ronco C, Mason G, et al. Cost-effectiveness analysis of online hemodi-
afiltration versus high-flux hemodialysis. ClinicoEconomics and Outcomes Research. 
2016;8:531-540
[78] Karkar A, Abdelrahman M, Locatelli F. A randomized trial on health-related patient 
satisfaction level with high-efficiency online hemodiafiltration versus high-flux dialysis. 
Blood Purification. 2015;40:84-91
[79] Mazairac AH, de Wit GA, Grooteman MP et al. Effect of hemodiafiltration on quality 
of life over time. Clinical Journal of the American Society of Nephrology. 2013;8:82-89
[80] Locatelli F, Altieri P, Andrulli S, et al. Predictors of haemoglobin levels and resistance to 
erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, hae-
mofiltration and haemodiafiltration: Results of a multicentre randomized and controlled 
trial. Nephrology Dialysis Transplantation. 2012;27:3594-3600
[81] Jia P, Jin W, Teng J, et al. Acute effects of hemodiafiltration versus conventional hemo-
dialysis on endothelial function and inflammation: A randomized crossover study. 
Medicine (Baltimore). 2016;95:e3440
Aspects in Dialysis130
[82] Canaud B, Bragg-Gresham JL, Marshall MR, et al. Mortality risk for patients receiv-
ing hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney 
International. 2006;69:2087-2093
[83] Panichi V, Rizza GM, Paoletti S, et al. Chronic inflammation and mortality in haemodi-
alysis: Effect of different renal replacement therapies. Results from the RISCAVID study. 
Nephrology Dialysis Transplantation. 2008;23:2337-2343
[84] Vilar E, Fry AC, Wellsted D, Tattersall JE, Greenwood RN, Farrington K. Long-term out-
comes in online hemodiafiltration and high-flux hemodialysis: A comparative analysis. 
Clinical Journal of the American Society of Nephrology. 2009;4:1944-1953
[85] Grooteman MP, van den Dorpel MA, Bots ML et al. Effect of online hemodiafiltration 
on all-cause mortality and cardiovascular outcomes. Journal of the American Society of 
Nephrology. 2012;23:1087-1096
[86] Maduell F, Moreso F, Pons M, et al. High-efficiency post-dilution online hemodiafil-
tration reduces all-cause mortality in hemodialysis patients. Journal of the American 
Society of Nephrology. 2013;24:487-497
[87] Maduell F, Moreso F, Mora-Macia J, et al. ESHOL study reanalysis: All-cause mortality 
considered by competing risks and time-dependent covariates for renal transplantation. 
Nefrología. 2016;36:156-163
[88] Ok E, Asci G, Toz H, et al. Mortality and cardiovascular events in online haemodiafil-
tration (OL-HDF) compared with high-flux dialysis: Results from the Turkish OL-HDF 
study. Nephrology Dialysis Transplantation. 2013;28:192-202
[89] van der Weerd NC, Den Hoedt CH, Blankestijn PJ, et al. Resistance to erythropoiesis 
stimulating agents in patients treated with online hemodiafiltration and ultrapure low-
flux hemodialysis: Results from a randomized controlled trial (CONTRAST). PloS One. 
2014;9:e94434
[90] Mostovaya IM, Bots ML, van den Dorpel MA, et al. A randomized trial of hemodiafiltra-
tion and change in cardiovascular parameters. Clinical Journal of the American Society 
of Nephrology. 2014;9:520-526
[91] Siriopol D, Canaud B, Stuard S, Mircescu G, Nistor I, Covic A. New insights into the 
effect of haemodiafiltration on mortality: The Romanian experience. Nephrology 
Dialysis Transplantation. 2015;30:294-301
[92] Mercadal L, Franck JE, Metzger M, et al. Hemodiafiltration versus hemodialysis and sur-
vival in patients with ESRD: The French Renal Epidemiology and Information Network 
(REIN) registry. The American Journal of Kidney Diseases. 2016;68:247-255
[93] Smith JR, Zimmer N, Bell E, Francq BG, McConnachie A, Mactier R. A randomized, 
single-blind, crossover trial of recovery time in high-flux hemodialysis and hemodiafil-
tration. The American Journal of Kidney Diseases. 2017;69:762-770
Cardiovascular Risk Factors in End-Stage Renal Disease Patients: The Impact of Conventional...
http://dx.doi.org/10.5772/intechopen.70465
131
[94] Rabindranath KS, Strippoli GF, Daly C, Roderick PJ, Wallace S, MacLeod AM. 
Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. 
Cochrane Database System Review. 2006; Oct 18;(4):CD006258
[95] Wang AY, Ninomiya T, Al-Kahwa A, et al. Effect of hemodiafiltration or hemofiltration 
compared with hemodialysis on mortality and cardiovascular disease in chronic kid-
ney failure: A systematic review and meta-analysis of randomized trials. The American 
Journal of Kidney Diseases. 2014;63:968-978
[96] Mostovaya IM, Blankestijn PJ, Bots ML, et al. Clinical evidence on hemodiafiltration: A 
systematic review and a meta-analysis. Seminars in Dialysis. 2014;27:119-127
[97] Nistor I, Palmer SC, Craig JC, et al. Haemodiafiltration, haemofiltration and haemo-
dialysis for end-stage kidney disease. Cochrane Database System Review. 2015; May 
20;(5):CD006258. DOI: 10.1002/14651858.CD006258.pub2
[98] Peters SA, Bots ML, Canaud B, et al. Haemodiafiltration and mortality in end-stage kid-
ney disease patients: A pooled individual participant data analysis from four random-
ized controlled trials. Nephrology Dialysis Transplantation. 2016;31:978-984
[99] Nube MJ, Peters SAE, Blankestijn PJ, et al. Mortality reduction by post-dilution online-
haemodiafiltration: A cause-specific analysis. Nephrology Dialysis Transplantation. 
2017;32:548-555
[100] Morena M, Jaussent A, Chalabi L, et al. Treatment tolerance and patient-reported 
outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the 
elderly. Kidney International. 2017;91:1495-1509
[101] Canaud B, Bowry SK. Emerging clinical evidence on online hemodiafiltration: Does 
volume of ultrafiltration matter? Blood Purification. 2013;35:55-62
[102] Davenport A, Peters SA, Bots ML, et al. Higher convection volume exchange with 
online hemodiafiltration is associated with survival advantage for dialysis patients: The 
effect of adjustment for body size. Kidney International. 2016;89:193-199
Aspects in Dialysis132
